[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Wang W, Li YF, Sun XW, Chen YB, Li W, Xu DZ, Guan XX, Huang CY, Zhan YQ, Zhou ZW: Prognosis of 980 patients with gastric cancer after surgical resection. Chin J Cancer; 2010 Nov;29(11):923-30
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of 980 patients with gastric cancer after surgical resection.
  • BACKGROUND AND OBJECTIVE: Although surgery is the only possible means to cure gastric cancer, the prognosis is often discrepant.
  • The American Joint Committee on Cancer / International Union against Cancer (AJCC/UICC) published the TNM classification of Malignant Tumors (seventh edition) for gastric cancer recently.
  • This study aimed to use this new edition staging system to investigate the prognostic factors for gastric cancer.
  • METHODS: The clinicopathologic data of 980 patients with gastric cancer treated by surgical resection in our hospital between January 2000 and December 2006 were analyzed retrospectively.
  • The 6th and 7th edition AJCC/UICC TNM staging systems were used to compare the survival outcomes for the cohort of patients.
  • The 5-year survival rates for patients with pTNM stage I, II, III, and IV disease classified by the 7th edition staging system were 93.2%, 72.4%, 39.1%, and 5.2%, respectively.
  • In both univariate analysis and Cox multivariate analysis, age, tumor site, tumor size, histological type, resection type, radical resection, lymphatic/venous invasion, depth of invasion, nodal status, metastasis, retrieved lymph nodes, metastatic lymph node ratio, and adjuvant chemotherapy were prognostic factors with these patients.
  • CONCLUSION: Compared with the 6th edition system, the new edition of TNM staging system for gastric cancer can accurately predict the survival after operation.
  • [MeSH-major] Adenocarcinoma. Gastrectomy. Neoplasm Staging / standards. Stomach Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20979691.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  •  go-up   go-down


2. Siakantaris MP, Pangalis GA, Dimitriadou E, Kontopidou FN, Vassilakopoulos TP, Kalpadakis C, Sachanas S, Yiakoumis X, Korkolopoulou P, Kyrtsonis MC, Bobotsis P, Androulaki A, Patsouris E, Panayiotidis P, Angelopoulou MK: Early-stage gastric MALT lymphoma: is it a truly localized disease? Oncologist; 2009 Feb;14(2):148-54
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early-stage gastric MALT lymphoma: is it a truly localized disease?
  • Early-stage gastric mucosa-associated lymphoid tissue lymphoma (GML) is considered a localized disease with an indolent course.
  • Circulating malignant cells have been detected in other early-stage indolent lymphomas by molecular methods.
  • We investigated the incidence of occult blood disease in early-stage GML patients, its impact on clinical outcome, and the similarity between blood and gastric lymphocytic clones.
  • Blood involvement was absent in all patients by conventional staging methods.
  • The monoclonal blood and gastric products of five patients were sequenced and compared with each other.
  • The VH3 gene was the most frequently used, both in the blood and in the stomach.
  • Early-stage GML is not a truly localized disease because half the patients had a circulating clone, probably identical to the gastric one.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. B-Lymphocytes / pathology. Female. Helicobacter Infections / blood. Helicobacter Infections / drug therapy. Helicobacter Infections / pathology. Humans. Immunoglobulin Heavy Chains / blood. Immunoglobulin Heavy Chains / genetics. Immunoglobulin Variable Region / genetics. Immunophenotyping. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Sequence Analysis, DNA. Treatment Outcome

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19204322.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region
  •  go-up   go-down


3. Wu Z, Ma JY, Yang JJ, Zhao YF, Zhang SF: Primary small cell carcinoma of esophagus: report of 9 cases and review of literature. World J Gastroenterol; 2004 Dec 15;10(24):3680-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To analyze the clinical manifestations, pathological features and treatment of primary small cell carcinoma (SCC) of the esophagus and to review the literature on this entity.
  • METHODS: The records of 9 patients with primary esophageal small cell carcinoma were examined and the demographic data, presenting symptoms, methods of tumor diagnosis, and types of treatment given, response to treatment, pathologic findings, and clinical outcome were reviewed.
  • They underwent radical resection, regional lymph node clearance and esophageal-stomach anastomosis in thorax or at neck.
  • They received adjuvant systemic chemotherapy and local radiation therapy after discharge.
  • During follow-up, three patients developed multiple liver, brain, lung and bone metastases and died between 5 and 18 mo after the diagnosis.
  • Three patients developed widespread metastasis disease and died between 18 and 37 mo after the diagnosis.
  • CONCLUSION: Primary small cell carcinoma of the esophagus is a rare but very malignant tumor.
  • Radical resection combined with chemotherapy and radiotherapy is helpful in limited stage cases.
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15534932.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 18
  • [Other-IDs] NLM/ PMC4612018
  •  go-up   go-down


Advertisement
4. Fukui T, Mitsudomi T: [Postoperative adjuvant chemotherapy for lung, gastric, colorectal and breast cancers]. Nihon Rinsho; 2010 Jun;68(6):1019-23
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative adjuvant chemotherapy for lung, gastric, colorectal and breast cancers].
  • The prognosis of the patients with malignant tumors who underwent complete resection is not necessarily satisfactory even in their early stages.
  • Perioperative adjuvant therapy has been expected as one of possible treatment options for improving patient's outcomes.
  • Recently, several randomized controlled trials and meta-analyses with a large number of enrolled patients have shown that postoperative adjuvant chemotherapy improves survival in patients with several solid tumors.
  • In this article, we reviewed the advances and current roles of adjuvant chemotherapy in major histology of solid tumors in Japan such as lung, gastric, colorectal and breast cancers.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Chemotherapy, Adjuvant. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery. Postoperative Care. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Female. Humans. Japan. Male. Meta-Analysis as Topic. Neoplasm Staging. Randomized Controlled Trials as Topic. Tegafur / administration & dosage. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives


5. Morifuji M, Murakami Y, Yokoyama Y, Sasaki M, Hayashidani Y, Toge K, Sueda T: [A case of recurrent gastric cancer with malignant ascites responding dramatically to chemotherapy with paclitaxel infused systemically and intraperitoneally]. Gan To Kagaku Ryoho; 2004 Nov;31(12):2027-30
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent gastric cancer with malignant ascites responding dramatically to chemotherapy with paclitaxel infused systemically and intraperitoneally].
  • We report a case in which chemotherapy with paclitaxel (TXL) infused systemically and intraperitoneally was effective for gastric cancer with malignant ascites.
  • A 69-year-old man suffering from advanced gastric cancer with peritoneal dissemination underwent distal gastrectomy, a radical C operation.
  • After chemotherapy with TS-1 and low-dose CDDP, TS-1 was administrated on an outpatient basis for 6 months.
  • However, he complained of abdominal fullness and ascites, and received combination chemotherapy with paclitaxel infused systemically and intraperitoneally as second-line treatment.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Ascites / drug therapy. Paclitaxel / administration & dosage. Peritoneal Neoplasms / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Drug Administration Schedule. Humans. Infusions, Intravenous. Infusions, Parenteral. Male. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15570933.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


6. Pratt BL, Greene FL: Role of laparoscopy in the staging of malignant disease. Surg Clin North Am; 2000 Aug;80(4):1111-26

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of laparoscopy in the staging of malignant disease.
  • Together with the fervor and benefits afforded by laparoscopic therapeutic interventions in the management of patients with benign disease and the diagnostic usefulness in blunt trauma and abdominal pain, awareness has been rekindled regarding the advantages of laparoscopy for the staging of abdominal malignancy.
  • Similarly, it is hoped that the use of systemic chemotherapy will achieve better specificity in cell destruction in patients identified laparoscopically to have uncontained disease in the abdominal cavity.
  • 7), both diagnostic and therapeutic, in the management of patients with abdominal malignancy will be limited only by the creativity and expertise of physicians and instrument makers.
  • [MeSH-major] Laparoscopy. Neoplasm Staging / methods. Neoplasms / pathology
  • [MeSH-minor] Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Female. Genital Neoplasms, Female / pathology. Genital Neoplasms, Female / surgery. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Lymphoma / pathology. Lymphoma / surgery. Palliative Care. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Prognosis. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10987027.001).
  • [ISSN] 0039-6109
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 82
  •  go-up   go-down


7. Hauenstein E, Seidl S, Schneider KT, Fischer T: Stillbirth in week 19 of pregnancy followed by maternal death as a consequence of refused chemotherapy for non-hodgkin's lymphoma--significance of adjuvant chemotherapy in women of reproductive age. Onkologie; 2010;33(12):692-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stillbirth in week 19 of pregnancy followed by maternal death as a consequence of refused chemotherapy for non-hodgkin's lymphoma--significance of adjuvant chemotherapy in women of reproductive age.
  • Especially in lymphomas, incidence and long-time survival have increased.
  • Hematologists and gynecologists have to treat more and more female patients who wish to become pregnant despite their disease and/or after finishing treatment.
  • CASE REPORT: We report on a 28-year-old patient with highly malignant non-Hodgkin's lymphoma (peripheral T cell lymphoma, Ann Arbor stage IV) and main manifestation at the gastric antrum, with a distinct wish for becoming pregnant.
  • Chemotherapy was strongly recommended to her, but she refused.
  • After she had conceived, the disease recurred, followed by stillbirth in week 19 of gestation and death due to gastric perforation and septic shock.
  • CONCLUSIONS: Facing the risk of sterility after chemotherapy should not induce patients to refuse chemotherapy and risk their lives.
  • Treatment of young female cancer patients should therefore always include a thorough discussion about other ways of preserving fertility for the time after treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / toxicity. Infertility, Female / chemically induced. Lymphoma, T-Cell, Peripheral / drug therapy. Lymphoma, T-Cell, Peripheral / surgery. Pregnancy Complications, Neoplastic / drug therapy. Pregnancy Complications, Neoplastic / surgery. Stillbirth. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery. Treatment Refusal
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / toxicity. Doxorubicin / administration & dosage. Doxorubicin / toxicity. Fatal Outcome. Female. Gastrectomy. Humans. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / toxicity. Pregnancy. Pregnancy Trimester, Second. Pyloric Antrum / pathology. Rupture, Spontaneous. Shock, Septic / pathology. Stomach Rupture / parasitology. Vincristine / administration & dosage. Vincristine / toxicity


8. Kinoshita K, Kondo K, Watanabe K: [A case of advanced gastric cancer with distant lymph node metastases in cervical, supraclavicular and superior mediastinum successfully treated with S-1/Cisplatin (CDDP)/Lentinan combination chemotherapy]. Gan To Kagaku Ryoho; 2010 Apr;37(4):707-10
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with distant lymph node metastases in cervical, supraclavicular and superior mediastinum successfully treated with S-1/Cisplatin (CDDP)/Lentinan combination chemotherapy].
  • An endoscopic examination revealed type 3 gastric cancer in the middle body of the stomach.
  • Histopathological study showed poorly-differentiated adenocarcinoma in both stomach and supraclavicular lymph node.
  • However, gastric endoscopic biopsy still showed a remnant malignant lesion.
  • After 5 courses of the chemotherapy, both the primary lesion and the distant lymph node swelling disappeared on gastroscopy and PET-CT, respectively, which was a so-called complete response(CR).
  • After that, only S-1 was administered for 3 weeks followed by a drug-free week as a course.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Head / pathology. Lentinan / therapeutic use. Neck / pathology. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Combinations. Female. Gastroscopy. Humans. Lymphatic Metastasis. Neoplasm Staging. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414031.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 37339-90-5 / Lentinan; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Fink W, Zimpfer A, Ugurel S: Mucosal metastases in malignant melanoma. Onkologie; 2003 Jun;26(3):249-51
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosal metastases in malignant melanoma.
  • BACKGROUND: We present the case of a patient with malignant melanoma stage IV according to the American Joint Committee on Cancer (AJCC) classification and an unusual pattern of metastasis to the mucosa of the esophagus, the stomach, the bladder and the palatine tonsil.
  • CASE REPORT: A 38-year-old male patient with metastatic malignant melanoma of stage III (AJCC) was admitted for initiation of adjuvant therapy.
  • Two cycles of dacarbazine (DTIC) chemotherapy were performed during which the patient developed cutaneous metastases, dyspepsia, and mild hematemesis.
  • Gastroscopy revealed bleeding from mucosal metastases of the esophagus and stomach.
  • A few weeks later the patient developed macroscopic hematuria.
  • [MeSH-major] Esophageal Neoplasms / secondary. Melanoma / secondary. Skin Neoplasms / pathology. Stomach Neoplasms / secondary. Tonsillar Neoplasms / secondary. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Gastric Mucosa / pathology. Humans. Male. Mucous Membrane / pathology. Neoplasm Staging. Tomography, Emission-Computed


10. Gheorghe C, Iacob R, Dumbrava M, Becheanu G, Ionescu M: Confocal laser endomicroscopy and ultrasound endoscopy during the same endoscopic session for diagnosis and staging of gastric neoplastic lesions. Chirurgia (Bucur); 2009 Jan-Feb;104(1):17-24
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Confocal laser endomicroscopy and ultrasound endoscopy during the same endoscopic session for diagnosis and staging of gastric neoplastic lesions.
  • INTRODUCTION: Confocal LASER endomicroscopy (CLE) is a newly developed endoscopic technique which allows subsurface in vivo histological assessment during ongoing endoscopy and targeted biopsies.
  • Ultrasound endoscopy (EUS) is a useful tool in staging upper GI malignant lesions.
  • We describe for the first time the use of both techniques during the same endoscopic session, in a pilot study, in order to increase the diagnostic yield of histological assessment and provide the staging of the gastric neoplastic lesions thus decreasing the time to therapeutic decision.
  • The indication of CLE/EUS exploration was the presence of a gastric polypoid lesion in 37% of cases, atypical gastric ulcer in 27% of patients, gastric lymphoma 18%, suspicion of gastric cancer recurrence after resection 9% and infiltrating type gastric cancer 9%.
  • Histological assessment after targeted biopsy has established the diagnosis of gastric adenocarcinoma in 55% of cases, gastric lymphoma in 18% of cases, gastric adenoma, gastric GIST and gastric foveolar hyperplasia in 9% of cases respectively.
  • In 2 patients - one case with suspected recurrent gastric cancer after surgery and one case of gastric lymphoma, CLE has indicated normal gastric mucosa.
  • The EUS evaluation showed in one gastric lymphoma patient a lesion interesting the mucosa and submucosa with regional adenopathy and a submucosal lesion with regional adenopathy in the other gastric lymphoma case.
  • The therapeutic decision was surgery in 73% of cases, chemotherapy and follow-up in 18% of cases and follow-up in 9% of cases.
  • CONCLUSION: CLE and EUS can be successfully associated during the same endoscopic session, for upper GI neoplastic lesions allowing targeted biopsies for histological assessment and disease staging for optimal therapeutic decision.
  • [MeSH-major] Endosonography. Microscopy, Confocal. Stomach Neoplasms / pathology. Stomach Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Diagnosis, Differential. Female. Gastric Mucosa / pathology. Gastric Mucosa / ultrasonography. Humans. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Reproducibility of Results. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19388564.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


11. Sun YJ, Zhao H, Guo YW, Lin F, Cai X, Tang XC, Yao Y: [Short-term effects of chemotherapy with combination of hydroxycamptothecine and oxaliplatin in the treatment of advanced digestive tract cancers]. Zhonghua Zhong Liu Za Zhi; 2004 Dec;26(12):749-52
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Short-term effects of chemotherapy with combination of hydroxycamptothecine and oxaliplatin in the treatment of advanced digestive tract cancers].
  • OBJECTIVE: To evaluate the short-term therapeutic effects and side effects of combined hydroxycamptothecine and oxaliplatin in the treatment of advanced digestive tract cancers.
  • METHODS: Thirty patients suffering from advanced digestive tract tumors including gastric cancer 8, colorectal cancer 20, cholecystic cancer 1 and malignant fibroadenoma 1 were studied.
  • Diarrhea developed in 42 cycles (54.5%) and 20 cycles (47.6%) grades III and IV.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Diarrhea / chemically induced. Female. Humans. Leukopenia / chemically induced. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15733397.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 67656-30-8 / 10-hydroxycamptothecin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


12. Toh U, Fujii T, Mishima M, Imaizumi T, Koga A, Yano S, Shirouzu K, Yahara T, Yamana H: [Conventional chemotherapy combined with the repetitive immune cell transfer for patients with refractory advanced gastric cancer]. Gan To Kagaku Ryoho; 2007 Nov;34(12):1931-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Conventional chemotherapy combined with the repetitive immune cell transfer for patients with refractory advanced gastric cancer].
  • In order to take advantage by both the anticancer effects and reconstruction of antitumor immunity, we compared the feasibility of a combination of CTL transfer and chemotherapy (ChT) for patients (pts) with malignant ascites due to carcinomatous peritonealitis of refractory gastric cancer to that of ChT only and/or cellular immunotherapy after failing ChT.
  • A total of 22 pts, 8 underwent only conventional ChT (Group A), 6 performed cellular IT after failing ChT (Group B) and 8 underwent combination therapy (Group C), were enrolled in this retrospective study.
  • ChT was based on conventional conditioning regimen with a standard dose for gastric cancer cases: S-1 (80-120 mg/body) plus paclitaxel (60-80 mg/m2), or CPT-11 (70-80 mg/m2) plus CDDP (80 mg/m2).
  • Autologous tumor cells stimulated with T lymphocytes (AuTL), a kind of CTL, were generated ex vivo from peripheral blood lymphocytes over a two-week co-culturing process with autologous tumor cells separating from the ascites.
  • The treatment was repeated at least three cycles with one-week interval.
  • Lymphocytes of ascites were evaluated for cytokine production and subset of CD4+CD25+ T cell before the treatment, and after 3 treatments.
  • The group C pts had increased IFN-gamma and IL-12 production with no TGF-beta1 responses by their ascites after 3 treatments.
  • These data show that combination therapy of CTL transfer and ChT is a feasible option for patients with refractory peritoneal carcinomatous of gastric cancer without serious adverse events.
  • Although it depends on each mechanism of IT and ChT, a more stringent evaluation of CTL transfer combined with ChT for refractory gastric cancer should be performed.
  • [MeSH-major] Combined Modality Therapy. Immunotherapy. Stomach Neoplasms / immunology. Stomach Neoplasms / therapy. T-Lymphocytes, Regulatory / immunology. T-Lymphocytes, Regulatory / transplantation
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cells, Cultured. Cytokines / metabolism. Female. Humans. Male. Middle Aged. Neoplasm Staging. Peritoneal Neoplasms / immunology. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy. RNA, Messenger / genetics. Receptors, Antigen, T-Cell / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219856.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cytokines; 0 / RNA, Messenger; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


13. Nakayama N, Koizumi W, Tanabe S, Sasaki T, Saigenji K: A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501). Gastric Cancer; 2006;9(3):185-91
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501).
  • BACKGROUND: Histologically diffuse-type gastric cancer is well known to have a poor prognosis and is often complicated with abdominal and pleural effusions.
  • We evaluated the efficacy of a low dose of cisplatin combined with methotrexate and 5-fluorouracil (MFP therapy) in diffuse-type advanced gastric cancer.
  • The median survival time was 211 days.
  • CONCLUSION: MFP therapy is useful for the management of diffuse-type inoperable and recurrent gastric cancer, even in patients with conditions such as pleural effusion, ascites, or lymphangitis carcinomatosa who have a poor prognosis or cannot eat solid food.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cisplatin / administration & dosage. Dose-Response Relationship, Drug. Female. Fluorouracil / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Staging. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / drug therapy. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer Clin Oncol. 1985 Nov;21(11):1321-4 [4076293.001]
  • [Cites] Cancer Treat Rep. 1986 Oct;70(10):1215-7 [3756943.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3813-8 [8508349.001]
  • [Cites] Eur J Cancer. 1994;30A(9):1263-9 [7999410.001]
  • [Cites] J Clin Oncol. 1992 Jun;10(6):912-22 [1375284.001]
  • [Cites] Eur J Cancer. 1994;30A(14):2091-3 [7857709.001]
  • [Cites] Eur J Cancer. 1990 Jan;26(1):63-5 [2138482.001]
  • [Cites] Gan To Kagaku Ryoho. 1992 Jul;19(7):946-53 [1626950.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Dec;83(23):8923-5 [3466165.001]
  • [Cites] Cancer Res. 1977 Jan;37(1):327-8 [830420.001]
  • [Cites] Cancer Treat Rep. 1984 Dec;68(12):1497-8 [6542449.001]
  • [Cites] Eur J Surg Oncol. 1987 Jun;13(3):203-6 [3036603.001]
  • [Cites] Anticancer Res. 1994 May-Jun;14(3B):1277-9 [8067696.001]
  • [Cites] Science. 1979 Sep 14;205(4411):1135-7 [472732.001]
  • [Cites] J Biol Chem. 1981 Feb 25;256(4):1695-704 [6161926.001]
  • [Cites] Gastric Cancer. 2000 Aug 4;3(1):19-23 [11984704.001]
  • [Cites] Jpn J Clin Oncol. 2004 Jun;34(6):316-22 [15333683.001]
  • [Cites] Ann Oncol. 1991 Nov-Dec;2(10):751-4 [1801881.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Oct;77(10):5663-7 [6160578.001]
  • [Cites] Am J Clin Oncol. 1983 Feb;6(1):35-8 [6682284.001]
  • [Cites] Gan To Kagaku Ryoho. 1987 Aug;14(8):2482-90 [3619460.001]
  • [Cites] Cancer. 1984 Jan 1;53(1):18-22 [6317158.001]
  • [Cites] Cancer Treat Rep. 1985 Apr;69(4):449-50 [4039628.001]
  • [Cites] Gastric Cancer. 1999 May;2(1):52-56 [11957071.001]
  • [Cites] Eur J Cancer Clin Oncol. 1983 Jun;19(6):717-20 [6683644.001]
  • [Cites] N Engl J Med. 1983 Nov 3;309(18):1094-104 [6353235.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1407-12 [7882343.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(3):167-72 [8500219.001]
  • [Cites] Surg Oncol. 1992 Jun;1(3):215-21 [1341254.001]
  • [Cites] Gastric Cancer. 2001;4(4):212-8 [11846065.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(1):67-8 [2720894.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2640-7 [7989939.001]
  • [Cites] Cancer Treat Rep. 1982 Sep;66(9):1713-7 [7116348.001]
  • [Cites] Cancer Res. 1973 Dec;33(12):3091-5 [4760525.001]
  • [Cites] Lancet. 1986 Feb 1;1(8475):256-8 [2868265.001]
  • (PMID = 16952036.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


14. Li Q, Feng FY, Chen Q, Jiao SC, Li F, Wang HQ, Huang WX, Ling CQ, Li MZ, Ren J, Zhang Y, Qin FZ, Zhou MZ, Zhu RZ: [Multicenter phase II clinical trial of uroacitides injection in the treatment for advanced malignant tumors]. Zhonghua Zhong Liu Za Zhi; 2008 Jul;30(7):534-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multicenter phase II clinical trial of uroacitides injection in the treatment for advanced malignant tumors].
  • OBJECTIVE: To investigate the efficacy, safety and the life quality improvement of uroacitides injection in the treatment for patients with advanced malignant tumors.
  • METHODS: A total of 160 patients with advanced stage cancers were enrolled into this multicenter, open and non-randomized phase II clinical trial, including cancers of the lung (33 cases), liver (45 cases), breast (17 cases), esophagus (11 cases), stomach (18 cases), colon (19 cases), pancreas (3 cases) and kidney (4 cases), and glioma (10 cases).
  • [MeSH-major] Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Methyltransferases / therapeutic use. Peptides / therapeutic use. Phenylacetates / therapeutic use
  • [MeSH-minor] Breast Neoplasms / blood. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Catheterization, Central Venous. Colorectal Neoplasms / blood. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / pathology. Humans. Nausea / chemically induced. Neoplasm Staging. Quality of Life. Remission Induction. Salvage Therapy. Treatment Outcome. Vomiting / chemically induced. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19062723.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial, Phase II; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / Peptides; 0 / Phenylacetates; 0 / alpha-Fetoproteins; 0 / cell differentiation agent II; EC 2.1.1.- / Methyltransferases
  •  go-up   go-down


15. Pavlidis N, Aamdal S, Awada A, Calvert H, Fumoleau P, Sorio R, Punt C, Verweij J, van Oosterom A, Morant R, Wanders J, Hanauske AR: Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG). Cancer Chemother Pharmacol; 2000;46(2):167-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG).
  • PATIENTS AND METHODS: Carzelesin was used as second- or third-line chemotherapy in patients with breast, ovarian, head and neck cancer and non-Hodgkin's lymphoma, and as first-line chemotherapy in patients with colorectal and gastric cancer and melanoma.
  • The drug was given as a bolus infusion at a 4-weekly dose of 150 microg/m2.
  • CONCLUSIONS: At this dose and schedule carzelesin did not yield activity in the types of tumors studied.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzofurans / therapeutic use. Indoles / therapeutic use. Neoplasms / drug therapy. Prodrugs / therapeutic use
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / drug therapy. Colorectal Neoplasms / drug therapy. Female. Head and Neck Neoplasms / drug therapy. Humans. Infusions, Intravenous. Lymphoma, Non-Hodgkin / drug therapy. Male. Melanoma / drug therapy. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / drug therapy. Stomach Neoplasms / drug therapy


16. Verreet PR, Schmidt WU, Müller FP: [Primary gastric lymphoma]. Chirurg; 2004 May;75(5):547-56; quiz 557-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary gastric lymphoma].
  • Primary gastric lymphoma derives from a secondary MALT system developing after a reaction of the immune system, e.g. following chronic gastritis induced by Helicobacter pylori.
  • Morphologically, follicular hyperplasia is found in the gastric mucosa.
  • The pathoetiologic model confirms the transformation of a malignant lymphoma from low grade to high grade by demonstrating increasing autonomous proliferation and, finally, uncontrolled dissemination.
  • Modern diagnostic tools are essential for staging and planning an adequate therapeutic strategy.
  • At present, the therapeutic strategies regarding primary lymphoma are under discussion.
  • Nevertheless, the consensus of international medical and surgical associations still recommends surgical therapy with curative intention for low-grade malignant lymphomas staged I 2-II 2.
  • In cases of high-grade malignant lymphoma, conservative therapy is supposed to be similarly successful.
  • The recent success of noninvasive therapeutic concepts seems to justify the application of triple eradication medication in case of Hp infection as well as radio- and chemotherapy in low- and high-grade malignant lymphomas.
  • However, in cases of nonremission or therapy-associated complications such as uncontrollable bleeding or tumor perforation, surgery is the only therapeutic option.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Anti-Ulcer Agents / therapeutic use. Cell Transformation, Neoplastic / pathology. Combined Modality Therapy. Gastrectomy. Gastric Mucosa / pathology. Gastritis / complications. Gastritis / drug therapy. Gastritis / pathology. Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Helicobacter Infections / pathology. Helicobacter pylori. Humans. Neoplasm Staging. Practice Guidelines as Topic. Prognosis

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):895-901 [10705011.001]
  • [Cites] Lancet. 1995 Jun 24;345(8965):1591-4 [7783535.001]
  • [Cites] Gastroenterology. 1992 May;102(5):1628-38 [1568573.001]
  • [Cites] Dtsch Med Wochenschr. 1994 Jun 17;119(24):863-8 [8005064.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1255-60 [8608213.001]
  • [Cites] Lancet. 1994 Jun 11;343(8911):1503 [7911202.001]
  • [Cites] Ann Oncol. 1993 Dec;4(10):839-46 [8117603.001]
  • [Cites] Praxis (Bern 1994). 1996 Nov 5;85(45):1451-4 [8975356.001]
  • [Cites] Lancet. 1992 Mar 21;339(8795):745-6 [1347613.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):575-7 [8102719.001]
  • [Cites] Gut. 2003 Jun;52(6):912-3 [12740354.001]
  • [Cites] Gut. 2004 Jan;53(1):34-7 [14684573.001]
  • [Cites] Ann Intern Med. 1995 May 15;122(10):767-9 [7717599.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1662-71 [8253342.001]
  • (PMID = 15118792.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Ulcer Agents
  •  go-up   go-down


17. Foukakis T, Lundell L, Gubanski M, Lind PA: Advances in the treatment of patients with gastric adenocarcinoma. Acta Oncol; 2007;46(3):277-85
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the treatment of patients with gastric adenocarcinoma.
  • Despite a decline in its incidence in the Western world, gastric cancer (GC) remains the fourth most frequent cancer diagnosis worldwide and is, after lung cancer, the second leading cause of death from a malignant disease globally.
  • Based on the published literature, treatment guidelines and reports from international meetings, we here review the current treatment options for GC and discuss insights and perspectives from the latest clinical studies.
  • However, less than one third of patients have a resectable disease at diagnosis and among those operated, more than half are not cured by surgery alone, due to a high rate of relapse.
  • Thus, for the majority of patients, systemic cytotoxic therapy, and sometimes radiotherapy, is a treatment option both as an adjunct to surgery and in the palliative setting.
  • Adjuvant chemotherapy offers only a marginal benefit and has not become a standard of care in the West.
  • Furthermore, a recently reported study from the United Kingdom demonstrated a significant disease-free and survival benefit by the use of perioperative combination chemotherapy.
  • Several chemotherapeutic agents have been tested as a palliative therapy in advanced GC including 5- fluorouracil (5-FU), oral pyrimidines, platinum derivatives, anthracyclines, taxanes and camptothecans.
  • It is now accepted that chemotherapy is better than best supportive care only and that 5-FU based combinations are more effective than monotherapy.
  • However, the response rates have generally been moderate and there is no consensus on the optimal combination of cytotoxic agents and the potential role of more recently developed "targeted therapies".
  • [MeSH-major] Adenocarcinoma / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Gastrectomy. Humans. Neoadjuvant Therapy. Neoplasm Staging. Palliative Care

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17450463.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 68
  •  go-up   go-down


18. Koschmieder S, Fauth F, Kriener S, Hoelzer D, Seipelt G: Effective treatment of simultaneous small cell lung cancer and B-cell lymphoma. Leuk Lymphoma; 2002 Mar;43(3):645-7
Genetic Alliance. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of simultaneous small cell lung cancer and B-cell lymphoma.
  • Malignant lymphomas have been reported previously to coincide with adenocarcinomas of the stomach and, rarely, the kidney, breast, colon, liver, or lung.
  • Here, we describe the first case to our knowledge of a malignant lymphoma and an extensive disease small cell cancer of the lung.
  • A B-cell non-Hodgkin's lymphoma (NHL) was diagnosed from biopsies of the stomach and liver.
  • Further staging revealed a dense infiltration of the bone marrow by both a small cell lung cancer and a malignant lymphoma.
  • Both tumors responded well to chemotherapy.
  • This unique case report demonstrates that the simultaneous occurrence of small cell lung cancers and malignant lymphomas is extremely rare and may effectively be treated with chemotherapy.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow / pathology. Humans. Liver / pathology. Male. Middle Aged. Neoplasm Invasiveness. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12002773.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


19. Lordick F, Grenacher L, Röcken C, Ebert M, Moehler M, Schumacher G: [Diagnosis and treatment of gastric cancer]. Dtsch Med Wochenschr; 2010 Aug;135(34-35):1671-82; quiz 1683-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of gastric cancer].
  • [Transliterated title] Diagnostik und Therapie des Magenkarzinoms.
  • From a global perspective, gastric cancer including cancer of the esophago-gastric junction is the fourth most common malignant tumor and the second-most common cause of cancer-related death.
  • Due to the lack of screening programs in Western countries, most gastric cancers are diagnosed in advanced stages.
  • A sophisticated staging should include high-resolution computed tomography of the thorax, abdomen and pelvis and video-documented endoscopy and endoscopic ultrasound.
  • In mucosal gastric cancer, endoscopic resection can replace surgical resection if specific criteria are present.
  • In the stages II and III perioperative chemotherapy has been established as a standard of care and should be applied.
  • In the metastatic setting, treatment goals are palliative.
  • Chemotherapy can prolong survival, improve symptoms and can help to maintain a better quality of life.
  • Combination chemotherapy including a platinum compound and a fluoropyrimidine regarded as standard.
  • About 20 % of gastric cancers exhibit overexpression of the growth factor receptor family member Her2.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cisplatin / administration & dosage. Endoscopy, Digestive System. Epirubicin / administration & dosage. Esophagectomy. Fluorouracil / administration & dosage. Gastrectomy. Gastric Mucosa / pathology. Humans. Laparoscopy. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Staging. Neoplasm, Residual / diagnosis. Neoplasm, Residual / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart-New York.
  • (PMID = 20721843.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; FPEPIR regimen
  • [Number-of-references] 40
  •  go-up   go-down


20. Schmid KE, Kornek GV, Schüll B, Raderer M, Lenauer A, Depisch D, Lang F, Scheithauer W: Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed. Onkologie; 2003 Jun;26(3):255-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed.
  • BACKGROUND: Treatment with oxaliplatin plus raltitrexed has demonstrated an encouraging therapeutic index in patients with advanced colorectal cancer and malignant pleural mesothelioma.
  • The aim of this multi-institutional study was to determine the antitumor potential of this combination in patients with metastatic gastric cancer failing prior palliative first-line chemotherapy, and to reconfirm its favorable toxicity profile.
  • PATIENTS AND METHODS: 21 patients with metastatic gastric cancer, who progressed while on or within 6 months after discontinuing palliative first-line chemotherapy, participated in this study.
  • Median progression-free and overall survival from the onset of salvage chemotherapy was 2.0 and 4.5 months, respectively.
  • CONCLUSION: Despite reproducibility of a favorable toxicity profile of oxaliplatin + raltitrexed, our data suggest that this combination regimen has no substantial antitumor activity in patients with progressive, chemotherapeutically pretreated metastatic gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Palliative Care. Salvage Therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Quinazolines / administration & dosage. Quinazolines / adverse effects. Retreatment. Survival Rate. Thiophenes / administration & dosage. Thiophenes / adverse effects

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger GmbH, Freiburg
  • [CommentIn] Onkologie. 2003 Jun;26(3):214-5 [12845204.001]
  • (PMID = 12845210.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Quinazolines; 0 / Thiophenes; 04ZR38536J / oxaliplatin; FCB9EGG971 / raltitrexed
  •  go-up   go-down


21. Arai O, Kakutani A, Mouri H, Ikeda H, Notohara K, Matsueda K: [A case of advanced gastric cancer growing extramurally with gynecomastia and high hCG-beta serum level]. Gan To Kagaku Ryoho; 2010 Jul;37(7):1369-72
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer growing extramurally with gynecomastia and high hCG-beta serum level].
  • We describe a rare case of advanced gastric cancer with markedly high serum levels of human chorionic gonadotrophin beta subunit (hCG-beta).
  • The patient was a 51-year-old man admitted for a gastric tumor growing extramurally and multiple liver tumors revealed by computed tomography, with chief complaints of abdominal and breast mass.
  • Upper gastrointestinal endoscopy showed gastric cancer of Borrmann type 2 and biopsy specimens showed poorly-differentiated adenocarcinoma.
  • Pathological examination from liver tumor showed the tumor cells greatly resembled gastric tumor and were immunohistochemically positive for hCG-beta.
  • We diagnosed hCG-beta producing gastric cancer.
  • He received chemotherapy, but died of hepatic failure about 8 months after initial diagnosis.
  • When we see a patient with gynecomastia and the high serum hCG-beta levels, it is important that hCG-beta producing-gastric cancer should be considered as a possible malignant tumor of the stomach.
  • [MeSH-major] Chorionic Gonadotropin, beta Subunit, Human / blood. Gynecomastia / blood. Gynecomastia / etiology. Stomach Neoplasms / blood. Stomach Neoplasms / pathology
  • [MeSH-minor] Biopsy. Fatal Outcome. Humans. Liver Neoplasms / pathology. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647729.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


22. Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K: Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Cancer Invest; 2008 May;26(4):344-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
  • However, the clinical significance of the expression of MDR-related proteins p-glycoprotein (PGP), glutathione-s-transferases (GST-pi), topoisomerase-II (Topo-II) and lung resistance protein (LRP) in primary gastric cardiac adenocarcinoma (PGCA) remains unclear.
  • The expression of PGP, GST-pi, Topo-II and LRP in formalin-fixed paraffin-embedded tissue sections was determined by a labelled streptavidin-biotin immunohistochemical technique, and the results were analyzed in correlation with clinicopathological data.
  • None of these patients received chemotherapy prior to surgery.
  • RESULTS: The positive rates of expression of PGP, GST-pi, Topo-II and LRP in malignant tissues (49.2%, 75.4%, 68.1% and 58%, respectively) were all higher than that of the normal tissues(0, 30%, 20% and 0, respectively, P < 0.01).
  • The expression of PGP was closely related with clinicopathologic staging (staging 1/2 vs 3/4, 28.6% vs 58.3%, P < 0.05).
  • GST-pi expression status progressively increased with increasing differentiated degree (40%, 75.8% and 88.5%, P < 0.05) and clinicopathologic stage (staging 1/2 vs 3/4, 57.1% vs 83.3%, P < 0.05).
  • No significant differences with Topo-II expression were found in relation to the clinicopathologic stage (staging 1/2 vs 3/4, 57.1% vs 72.9%, P > 0.05) and lymphatic metastasis (with vs. without metastasis, 65.0% vs 72.4%, P > 0.05).
  • Moreover, a significant difference with the expression of LRP was found in relation to the clinicopathologic stage (staging 1/2 vs 3/4, 38% vs 66.6%, P < 0.05), and lymphatic metastasis (with vs without metastasis, 70.0% vs 41.4%, P < 0.05).
  • The positive rates of co-expression of PGP and GST-pi, PGP and Topo-II, PGP and LRP, GST-pi and Topo-II, LRP and GST-pi, LRP and Topo-II, PGP, GST-pi, Topo-II and LRP in malignant cells were 23.2%, 15.9%, 11.6%, 13.0, 26.1, 7.24, 5.8, respectively.
  • CONCLUSIONS: MDR-related proteins PGP, GST-pi, Topo-II alpha and LRP are involved in multiple mechanisms of drug resistance in PGCA.
  • Combined determination of PGP, GST-pi, Topo-II and LRP may be prospectively valuable for optimizing the chemotherapy regimes, developing high quality anti-cancer drugs, and further predicting the outcomes of those patients with PGCA.
  • [MeSH-major] Adenocarcinoma / chemistry. Cardia / chemistry. DNA Topoisomerases, Type II / analysis. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Gene Expression Regulation, Neoplastic. Glutathione S-Transferase pi / analysis. Neoplasm Proteins / analysis. P-Glycoprotein / analysis. Stomach Neoplasms / chemistry. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Organelles / chemistry. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18443954.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


23. Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K: Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Hepatogastroenterology; 2008 Sep-Oct;55(86-87):1530-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
  • However, the clinical significance of the expression of MDR-related proteins p-glycoprotein (PGP), glutathione-s-transferases (GST-pi), topoisomerase-II (Topo-II) and lung resistance protein (LRP) in primary gastric cardiac adenocarcinoma (PGCA) remains unclear.
  • The expression of PGP, GST-pi, Topo-II and LRP in formalin-fixed paraffin-embedded tissue sections was determined by a labelled streptavidin-biotin immunohistochemical technique, and the results were analyzed in correlation with clinicopathological data.
  • None of these patients received chemotherapy prior to surgery.
  • RESULTS: The positive rates of expression of PGP, GST-pi, Topo-II and LRP in malignant tissues (49.2%, 75.4%, 68.1% and 58%, respectively) were all higher than that of the normal tissues (0, 30%, 20% and 0, respectively, P<0.01).
  • PGP expression in tumors that had metastasized was significantly more frequent than in tumors that had not metastasized (67.5% vs. 24.1%, P<0.01).The expression of PGP was closely related with clinicopathologic staging (staging 1/2 vs. 3/4, 28.6% vs. 58.3%, P<0.05).
  • GST-pi expression status progressively increased with increasing differentiated degree (40%, 75.8% and 88.5%, P<0.05) and clinico pathologic stage (staging 1/2 vs. 3/4, 57.1% vs. 83.3%, P<0.05).
  • No significant differences with Topo-II expression was found in relation to the clinicopathologic stage (staging 1/2 vs. 3/4, 57.1% vs. 72.9%, P>0.05) and lymphatic metastasis (with vs. without metastasis, 65.0% vs. 72.4%, P>0.05).
  • Moreover, a significant difference with the expression of LRP was found in relation to the clinicopathologic stage (staging 1/2 vs. 3/4, 38% vs. 66.6%, P<0.05), and lymphatic metastasis (with vs. without metastasis, 70.0% vs. 41.4%, P<0.05).
  • The positive rates of co-expression of PGP and GST-pi, PGP and Topo-II, PGP and LRP, GST-pi and Topo-II, LRP and GST-pi, LRP and Topo-II, PGP, GST-pi, Topo-II and LRP in malignant cells were 23.2%, 15.9%, 11.6%, 13.0%, 26.1%, 7.24%, 5.8%, respectively.
  • CONCLUSIONS: MDR-related proteins PGP, GST-pi, Topo-II and LRP are involved in multiple mechanisms of drug resistance in PGCA.
  • Combined determination of PGP, GST-pi, Topo-II and LRP may be prospectively valuable for optimizing the chemotherapy regimes, developing high quality anti-cancer drugs, and further predicting the outcomes of those patients with PGCA.
  • [MeSH-major] Adenocarcinoma / chemistry. Cardia / chemistry. DNA Topoisomerases, Type II / analysis. Glutathione S-Transferase pi / analysis. P-Glycoprotein / analysis. Stomach Neoplasms / chemistry. Vault Ribonucleoprotein Particles / analysis
  • [MeSH-minor] Adult. Aged. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102336.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / P-Glycoprotein; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


24. Curtis JL, Burns RC, Wang L, Mahour GH, Ford HR: Primary gastric tumors of infancy and childhood: 54-year experience at a single institution. J Pediatr Surg; 2008 Aug;43(8):1487-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastric tumors of infancy and childhood: 54-year experience at a single institution.
  • BACKGROUND/PURPOSE: Primary gastric tumors are rare in infancy and childhood.
  • METHODS: During the period extending from 1952 to 2006, 21 infants and children with primary gastric tumors were treated at Children's Hospital Los Angeles.
  • RESULTS: There were 12 males and 9 females, aged 12 days to 18 years, who were diagnosed with gastric tumors.
  • Morphological analysis revealed gastric stromal tumors (n = 6), teratomas (n = 4), lymphomas (n = 4), adenocarcinomas (n = 2), inflammatory myofibroblastic tumors (n = 2), embryonal rhabdomyosarcoma (n = 1), and hamartomas (n = 3).
  • There were 16 patients still alive (mean follow-up, 22.3 months), whereas 6 died from active disease despite multimodal treatment.
  • CONCLUSIONS: Gastric tumors in children are rare.
  • Most malignant tumors present at an advanced stage and carry a substantial rate of mortality.
  • In the case of some malignancies, chemotherapy may play a major role.
  • Metastatic evaluation should be performed in all patients with malignant gastric tumors.
  • [MeSH-major] Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Stromal Tumors / therapy. Stomach Neoplasms / pathology. Stomach Neoplasms / therapy
  • [MeSH-minor] Adolescent. Anastomosis, Roux-en-Y. Biopsy, Needle. Chemotherapy, Adjuvant. Child. Child, Preschool. Cohort Studies. Combined Modality Therapy. Female. Gastrectomy / methods. Humans. Immunohistochemistry. Infant. Infant, Newborn. Male. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Risk Assessment. Survival Analysis. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18675640.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Sasaki Y, Niwa Y, Ando N, Otsuka Y, Ohmiya N, Hirooka Y, Itoh A, Furuta S, Goto H: Efficacy of STI571 for a patient with metastatic gastrointestinal stromal tumor. Hepatogastroenterology; 2005 Nov-Dec;52(66):1764-7
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He was diagnosed as having a gastrointestinal stromal tumor arising from the stomach.
  • He was medicated with STI571, which works by blocking proliferation of malignant cells with expression of c-kit.
  • [MeSH-major] Gastrointestinal Neoplasms / drug therapy. Gastrointestinal Neoplasms / pathology. Gastrointestinal Stromal Tumors / drug therapy. Gastrointestinal Stromal Tumors / pathology. Palliative Care. Piperazines / administration & dosage. Pyrimidines / administration & dosage
  • [MeSH-minor] Aged. Benzamides. Biopsy, Needle. Disease Progression. Dose-Response Relationship, Drug. Drug Administration Schedule. Fatal Outcome. Humans. Imatinib Mesylate. Immunohistochemistry. Male. Neoplasm Staging. Risk Assessment. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334774.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down






Advertisement